Survodutide
aka BI 456906
GLP-1 / Metabolic
Mechanism
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Identification
Vendors selling Survodutide
No vendor listings on file yet.
Research
No citations on file yet.